AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00705874
Drug: CGC-11047 and docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel: (Closed to enrollment) 75 mg/m2 administered IV over 60 minutes every 21 days. CGC-11047 will be administered only on Day 1 of each 21-day cycle and will start at dose level -1 (50 mg).
Trial: NCT00705874
Drug: CGC-11047 and bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab: 5 mg/kg administered IV once every 14 days. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.
Trial: NCT00705874
Drug: CGC-11047 and erlotinib
RxNorm normalized name: CGC-11047
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erlotinib: 150 mg taken orally every day of each 28-day cycle. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.
Trial: NCT00705874
Drug: CGC-11047 and cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin: 80 mg/m2 administered IV over 1 hour once every 28 days. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.
Trial: NCT00705874
Drug: CGC-11047 and sunitinib
RxNorm normalized name: CGC-11047
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sunitinib: 50 mg orally once daily, 4 weeks on treatment followed by 2 weeks off (42 day cycle). CGC-11047 will be administered on Days 1 and 8 of a 21 day cycle.
Trial: NCT02326727
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epidural analgesia
Trial: NCT02326727
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: General Anesthesia
Trial: NCT02326727
Drug: Isoflurane
RxNorm normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: General Anesthesia
Trial: NCT02326727
Drug: Nitrous Oxide
RxNorm normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: General Anesthesia
Trial: NCT01459666
Drug: Dysport (abobotulinumtoxinA)
RxNorm normalized name: Dysport
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Intramuscular injection effects lasting up to 3 months
Trial: NCT01459666
Drug: Bacteriostatic 0.9% Sodium Chloride (vehicle)
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular injection
Trial: NCT00724100
Drug: ALB 109564(a) (12´-methylthiovinblastine dihydrochloride)
RxNorm normalized name: darbepoetin alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Starting dose is 1.2 mg/m2. Standard dose increase, in the absence of limiting toxicity, is 50%. Each dose of ALB 109564(a) will be administered by intravenous infusion once every 3 weeks (21-day cycle) over a period of time up to approximately 30 minutes. Number of cycles: Maximum of 12, until disease progression, or unacceptable toxicity develops. Greater than 12 cycles if disease has not progressed after 12 cycles, with Investigator's and Sponsor's approvals.
Trial: NCT01929200
Drug: 1-year treatment with icotinib
RxNorm normalized name: icotinib
DrugBank: Icotinib (DB11737)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Icotinib is administered orally with a dose 125 mg 3 times daily within 4-6 weeks after operation for 1 year.
Trial: NCT01929200
Drug: 2-year treatment with icotinib
RxNorm normalized name: miconazole
DrugBank: Icotinib (DB11737)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Icotinib is administered orally with a dose 125 mg 3 times daily within 4-6 weeks after operation for 2 years.
Trial: NCT04169464
Drug: Sofosbuvir Oral Product
RxNorm normalized name: sofosbuvir Oral Product
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: to investigate the drug effect on renal function and insulin resistance
Trial: NCT00533429
Drug: enzastaurin
RxNorm normalized name: Enzastaurin
DrugBank: Enzastaurin (DB06486)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1125 milligram (mg) loading dose then 500 mg, oral, daily until disease progression
Trial: NCT00533429
Drug: pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 500 milligrams per square meter (mg/m\^2), intravenously ( IV), Day 8 of cycle 1 - 28 days, Day 1 of subsequent cycles every (q) 21 days x 3 cycles
Trial: NCT00533429
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Area under the curve (AUC) 6, IV, Day 8 cycle 1 - 28 days, Day 1 of subsequent cycles q 21 days x 3 cycles
Trial: NCT00533429
Drug: bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 15 milligrams/kilogram (mg/kg), IV, Day 8 of cycle 1 - 28 days, Day 1 of subsequent cycles q 21 days x 3 cycles
Trial: NCT02072954
Drug: Asenapine Sublingual Tablets 10 mg
RxNorm normalized name: asenapine Sublingual Tablet
DrugBank: Asenapine (DB06216)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: White to off-white, round, uncoated,unscored, flat-faced radius edge tablet. Debossed with A on one side and 17 on the other side
Trial: NCT02072954
Drug: Asenapine Sublingual Tablets 10 mg
RxNorm normalized name: asenapine Sublingual Tablet
DrugBank: Asenapine (DB06216)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Round, white to off-white sublingual tablets, with 10 on one side within a circle
Trial: NCT00202696
Drug: nalmefene
RxNorm normalized name: Nalmefene
DrugBank: Nalmefene (DB06230)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Nalmefene HCl film-coated tablets administered orally, twice daily, for total daily dosage of 40 or 80 mg, for 5 weeks (following a 2-week titration period).
Trial: NCT03809273
Drug: Trimetazidine
RxNorm normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine 20mg/tid
Trial: NCT03809273
Drug: Yangxinshi mimic
RxNorm normalized name: Bfkb-8488a (bispecific antibody designed to mimic the metabolic hormone fgf21).
DrugBank: Fazpilodemab (DB18924)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yangxinshi mimic tablets 3 pills /tid
Trial: NCT03809273
Drug: Trimetazidine mimic
RxNorm normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine mimic tablets 20mg/tid
Trial: NCT00602524
Drug: Pilocarpine
RxNorm normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00816075
Drug: distilled water
RxNorm normalized name: Distilled Water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: we plan to administer 200ml of distilled water after TUR of the tumor and block the catheter for 2 hours
Trial: NCT02512380
Drug: Docetaxel;oxaliplatin;s1
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Docetaxel 60mg/m2 was administered on day 1 of every 14 days.oxaliplatin 85 mg/m2 was administered on day 2 every 14 days. 40-60 mg of oral S-1 according to body-surface area twice a day was given for 10 days every 14 days .
Trial: NCT02512380
Drug: oxaliplatin;s1
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oxaliplatin 100 mg/m2 on day 1 every 21 days.40-60 mg of oral S-1 according to body-surface area twice a day was given for 2 weeks every 21 days .
Trial: NCT00233532
Drug: Trandolapril
RxNorm normalized name: Trandolapril
DrugBank: Trandolapril (DB00519)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5, 1,2,4mg/once daily/ for 26 weeks (If BP was not controlled, dose was escalated to the next higher dosage every 4-5 weeks).
Trial: NCT02569346
Drug: Triumeq
RxNorm normalized name: Triumeq
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single-dose Triumeq as a whole tablet
Trial: NCT02569346
Drug: Triumeq crushed + breakfast
RxNorm normalized name: Triumeq
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single-dose crushed and suspended tablet of Triumeq
Trial: NCT02569346
Drug: Triumeq crushed + drip feed
RxNorm normalized name: Triumeq
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Drip feed followed by single-dose crushed and suspended tablet of Triumeq
Trial: NCT02717325
Drug: Coppertone (BAY987517)
DrugBank: Copper (DB09130)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.(Formulation- SR16-08)
Trial: NCT03738722
Drug: Oxygen
RxNorm normalized name: Oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HFNCT (high flow nasal cannula therapy) will be provided using OptiFlow by Fisher\&Paykel.
Trial: NCT02592421
Drug: Dapagliflozin
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: SGLT2 inhibitor (dapagliflozin)
Trial: NCT03506620
Drug: Ropivacaine injection
RxNorm normalized name: ROPivacaine Injection
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naropin (Ropivacaine HCl) 0.25%; Dose: 20 cc
Trial: NCT01979679
Drug: Lurasidone 80 mg
RxNorm normalized name: lurasidone 80 mg oral tablet
DrugBank: Lurasidone (DB08815)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01979679
Drug: Lurasidone 120 mg
RxNorm normalized name: lurasidone 120 mg oral tablet
DrugBank: Lurasidone (DB08815)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01979679
Drug: Lurasidone 160 mg
DrugBank: Lurasidone (DB08815)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00509327
Drug: bisacodyl
RxNorm normalized name: Bisacodyl
DrugBank: Bisacodyl (DB09020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10mg capsule twice daily from one day preoperatively to day three postoperatively
Trial: NCT02449941
Drug: PPI (proton pump inhibitor)
RxNorm normalized name: PPI-1040
DrugBank: PPI-1040 (DB17620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Pre ESD (endoscopic submucosal dissection)~   * Assessment atrophy and metaplasia in stomach, Check Helicobacter pylori~  * Use of PPI for 2 months~2. Post ESD 1 (After 2 months)~   * Assess the distribution of helicobacter pylori after using PPI.~  * Stop of PPI~3. Post ESD 2 (After 4 months)~   * Assess the distribution of helicobacter pylori after stop of PPI.
Trial: NCT03111212
Drug: Iloprost
RxNorm normalized name: Iloprost
DrugBank: Iloprost (DB01088)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iloprost nebulized
Trial: NCT03111212
Drug: control
RxNorm normalized name: Control
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sodium chloride 0,9% nebulized
Trial: NCT02739958
Drug: Propofol group
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anesthesia is maintained with continuous infusion of propofol 1.5-2mg/kg/h and dexmedetomidine 0.2-1ug/kg/h.
Trial: NCT02739958
Drug: Isoflurane group
RxNorm normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anesthesia was maintained with isoflurane at a concentration of 2-2.5%. fentanyl 50 ug increments
Trial: NCT00803361
Drug: Duloxetine
RxNorm normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60 to 120 mg, capsules, oral, once a day for 15 weeks
Trial: NCT00318929
Drug: Divalproex Sodium Extended-Release Tablets
RxNorm normalized name: Divalproex Sodium Extended-Release Tablets
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once a day dosing
Trial: NCT00006356
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00006356
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00127881
Drug: HuMax-CD4 (zanolimumab)
RxNorm normalized name: Humax-cd4
DrugBank: Zanolimumab (DB17376)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal Antibody, 12 weekly infusions.
Trial: NCT00426803
Drug: activated recombinant human factor VII
RxNorm normalized name: Activated Recombinant Human Factor VII, Long Acting
DrugBank: Eptacog alfa pegol (activated) (DB11661)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01734824
Drug: Denosumab
RxNorm normalized name: Denosumab
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: sc RANKL-inhibitor
Trial: NCT01734824
Drug: Teriparatide
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: daily subcutaneous injection of teriparatide
Trial: NCT01734824
Drug: Placebo Denosumab
RxNorm normalized name: Denosumab
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: one subcutaneous injection denosumab placebo
Trial: NCT01734824
Drug: Placebo Teriparatide
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: daily subcutaneous placebo injection
Trial: NCT00405249
Drug: elvucitabine
RxNorm normalized name: Elvucitabine
DrugBank: Elvucitabine (DB06236)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02077231
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: use one drop in the eye
Trial: NCT02077231
Drug: carbomer eye gel
DrugBank: Carbomer (DB15649)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: use one drop in the eye
Trial: NCT03069508
Drug: Clemizole Hydrochloride
RxNorm normalized name: Clemizole
DrugBank: Clemizole (DB15932)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clemizole Hydrochloride will be administered orally for up to 24 weeks
Trial: NCT02453893
Drug: Iloperidone
RxNorm normalized name: Iloperidone
DrugBank: Iloperidone (DB04946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02453893
Drug: Risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01122979
Drug: INSULIN GLARGINE
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical form: 100 Units/mL solution for injection in a pre-filled SoloStar pen (3 mL) Route of administration: subcutaneous Dose regimen: dose adjusted to the patient's glycemia
Trial: NCT01122979
Drug: NPH insulin (insulin isophane)
RxNorm normalized name: INSULIN,NPH,BEEF
DrugBank: Beef (DB10509)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: dose adjusted to the patient's glycemia
Trial: NCT01122979
Drug: INSULIN GLULISINE
RxNorm normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pharmaceutical form: 100 Units/mL solution for injection in a pre-filled SoloStar pen (3 mL) Route of administration: subcutaneous Dose regimen: dose adjusted to the patient's glycemia
Trial: NCT01186250
Drug: Pioglitazone
RxNorm normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15mg pioglitazone taken daily for one month, 30mg pioglitazone taken daily for another month, 45mg pioglitazone taken daily for remaining ten months
Trial: NCT00368030
Drug: Eszopiclone
RxNorm normalized name: Eszopiclone
DrugBank: Eszopiclone (DB00402)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eszopiclone 3 mg QD
Trial: NCT02273102
Drug: Tranylcypromine
RxNorm normalized name: Tranylcypromine
DrugBank: Tranylcypromine (DB00752)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranylcypromine (TCP) to be administered orally twice a day (12 hours apart) for up to 16 cycles of 21 days each.
Trial: NCT00800982
Drug: etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Etanercept is given at the standard FDA approved dosage of 50 mg twice weekly x 3 months then 50 mg once weekly x 3 months.
Trial: NCT00499200
Drug: SRA-444
RxNorm normalized name: SRA-737
DrugBank: SRA-737 (DB16876)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01655186
Drug: Bardoxolone Methyl
RxNorm normalized name: Bardoxolone methyl
DrugBank: Bardoxolone methyl (DB05983)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04631315
Drug: Difluprednate Ophthalmic Emulsion 0.05%
DrugBank: Difluprednate (DB06781)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 drop, 2 times a day, starting the day before surgery and continuing for 14 post-surgical days and 1 drop, once a day for the next 2 weeks.
Trial: NCT04631315
Drug: Prednisolone Acetate 1% Phenylephrine hydrochloride 0,12% ophthalmic solution
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 drop, 4 times a day, starting the day before surgery and continuing for 14 post-surgical days and 1 drop, twice a day for the next 2 weeks.
Trial: NCT03762161
Drug: TAS 102
RxNorm normalized name: Ta
DrugBank: Tantalum (DB12859)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participant self-administered orally at 35 milligrams per meter squared (mg/m2) twice daily Days 1-5 and 8-12 of every 28 day cycle
Trial: NCT03400241
Drug: Tiotropium Bromide Monohydrate
RxNorm normalized name: tiotropium bromide monohydrate
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium Easyhaler 10 mcg/dose Product A
Trial: NCT03400241
Drug: Tiotropium Bromide Monohydrate
RxNorm normalized name: tiotropium bromide monohydrate
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium Easyhaler 10 mcg/dose Product B
Trial: NCT03400241
Drug: Tiotropium Bromide Monohydrate
RxNorm normalized name: tiotropium bromide monohydrate
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium Easyhaler 10 mcg/dose Product C
Trial: NCT03400241
Drug: Tiotropium Bromide Monohydrate
RxNorm normalized name: tiotropium bromide monohydrate
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spiriva 18 Mcg/capsule inhaled via HandiHaler
Trial: NCT03965182
Drug: PEG
RxNorm normalized name: PEG
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 sachets of PEG will be used as the bowel prep regimen.
Trial: NCT02706925
Drug: BI 443651
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00600067
Drug: Phentermine/Topiramate
RxNorm normalized name: PHENTERMINE/TOPIRAMATE
DrugBank: Phentermine (DB00191)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: phentermine 15mg/ topiramate controlled release (CR) 92mg, oral capsule, once daily, 28 weeks
Trial: NCT02132897
Drug: Tegretol CR 400 Single Dose-Auration CR 400 Single Dose
RxNorm normalized name: carbamazepine 400 MG [Tegretol]
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Auration CR 400 milligrams Single Dose is given orally with 250 mL of water at room temperature.
Trial: NCT00446329
Drug: cinacalcet
RxNorm normalized name: Cinacalcet
DrugBank: Cinacalcet (DB01012)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Initiation dose of cinacalcet 30 mg/day. Titration every 2-3 weeks with a maximum dose of 180 mg/day.
Trial: NCT02564588
Drug: Dasotraline
RxNorm normalized name: Dasotraline
DrugBank: Dasotraline (DB12305)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dasotraline 4, 6, 8mg flexibly dosed once daily
Trial: NCT01224236
Drug: control
RxNorm normalized name: Control
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: multivitamin solution without iron
Trial: NCT02404168
Drug: lamotrigine (brand Lamictal)
RxNorm normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: an anti-epileptic drug (brand)
Trial: NCT02404168
Drug: lamotrigine (generic Teva)
RxNorm normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: an anti-epileptic drug (brand)
Trial: NCT04292197
Drug: 18-MC Compound
RxNorm normalized name: Blackburn Compound
DrugBank: Drostanolone propionate (DB14655)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 18-MC
Trial: NCT01842373
Drug: LMX4
RxNorm normalized name: LIDOCAINE 40 mg in 1 g TOPICAL CREAM [LMX4]
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00224081
Drug: Sodium ferric gluconate,
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium ferric gluconate, 125 mg IV given at 8 consecutive hemodialysis sessions
Trial: NCT00251693
Drug: Dexlansoprazole MR
RxNorm normalized name: Dexlansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dexlansoprazole MR 60 mg, capsules, orally, once daily (QD) for up to 8 weeks.
Trial: NCT00251693
Drug: Dexlansoprazole MR
RxNorm normalized name: Dexlansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dexlansoprazole MR 90 mg, capsules, orally, once daily for up to 8 weeks.
Trial: NCT00251693
Drug: Lansoprazole
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.
Trial: NCT01196013
Drug: Clofarabine
RxNorm normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous, 30 mg/m2, 52 mg/m2
Trial: NCT00442416
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: As prescribed, SC
Trial: NCT00442416
Drug: methoxy polyethylene glycol-epoetin beta [Mircera]
DrugBank: Methoxy polyethylene glycol-epoetin beta (DB09107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 120-360 micrograms SC monthly, starting dose